Loading...
NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
The heterogeneity of ALK tyrosine-kinase inhibitor (TKI) responses poses a puzzling question to clinicians. Different variants of ALK rearrangements might be one of the mechanisms explaining this phenomenon. Therefore, identifying specific fusion forms is crucial to clinical practice. This case repo...
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6369846/ https://ncbi.nlm.nih.gov/pubmed/30799936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S192367 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|